Mediwatch is a small company destined to become a much bigger fish by the time this year is out. Mediwatch are already a market leader in urological medical diagnostics equipement and are currently exporting their products throughout the UK, Canada, Europe, India and Japan. That doesn't leave much of the globe left for them to capture - until you remember the good ol' US and China. These are the two massive markets which are destined to be added to MDW's export client portfolio by the end of 2005.

Website: www.mediwatch.com

The company is currently heavily undervalued. This is probably because Mediwatch's speciality is not a very glamourous business to be in as their equipment is used extensively to diagnose prostate cancer in men and other nasty urological conditions affecting both men and women. However, don't let that put you off investing in these guys. This is big business and is growing at an exponential rate as more and more people globally become health-aware as they get older. Mediwatch normally supply their products through to global markets via distribution agreements. They already have the best of distribution partners in the well known US medical distributor CR Bard who supply Canada and Europe and GE Medical who supply Japan. The UK business is handled by Mediwatch's own dedicated sales team. US FDA approval was gained for MDW's products at the start of last year, however a whole year of US legal wrangling meant that they were unable to seek a suitable partner for the crucial distribution agreement until the start of this year. This distribution agreement is expected by the board to have a "significant effect" on the share price so they are reluctant to give any clues as to when it will be signed, sealed and delivered. The general consensus is that this US distribution agreement will be announced in July/August. In China and Hong Kong, MDW have done things the other way round. They have set up distribution agreements with major Asian medical equipment distributors and have stock already out there waiting to sell into the markets - all they are waiting for is SDA approval (which is a "rubber stamp") from the Chinese authorities - this can take anything up to 12 months to come through and MDW applied during Autumn 2004 - so even more good news coming soon this year. Epidemiological data from British Association of Urology conference last year: On average 30-45% of all men between the age of 50 and 70 have at least one PSA test per year in the US / Italy / Australia. If that's not enough to convince you to invest a few hard earned coppers in MDW, they are also developing a PSA stick test product (PSAWatch) which is revolutionary and causing some excitement in medical circles. This product can also be adapted (at very low cost) for a whole spectrum of medical disciplines from Cardiology to Veterinary Practice! This product is likely to be released in the next few weeks. Philip Stimpson the CEO has said that this product is going to be their "gold mine" - I'm sure it will prove to be ours too.

PSAwatch is a very attractive bonus to Mediwatch's Urology suite but by no means the main unit.For one thing the Bioscan (previously been posted)reads the PSA value and is designed to read any number of future tests!
It is fitting that we concentrate on PSAwatch at the moment for obvious reasons ie Prostate Awareness week and the official launch later in this week.

I also think (Ed-Here we go!)that our government along with others around the world are being taken to task over Prostate Cancer and what are you doing about it!
I do think there will be some sort of UK Gov.cash incentive to acquire PSAwatch at a more local level.It wouldn't cost that much and would put any Gov.in a good light as to be doing something,only my opinion mind.


That's the end of me ramblings-lol

closed out s/b short for a few points on the plus side....boring

Are you going long now treble?

BTW do you have to pay any premium on your SBs?

no not long.....flat....pay a small premium on the s/b...depends on volume usually...but if yiu are smart and watch l2 with spread and trades it is nealry like dealing in the shares

Have I missed something ? What has caused this little beauty to leap

Good job you're out of that short Treb - the thread heading is finally coming true - bit like the European space programme - 2 years late but definitely happening now - whoosh.

:))))))

Now I see why - great news - this could become a tenbagger

i hope trble close his short.............

calm down oak........i've had other small shares and people ramp them up.

a tidy profit will do me

Scot, Oak a bit enthusiastic this morning as I think we all must be. I can't say that ramping has played much part on this thread.
MDW has many products but this one (PSA test) is a world first and a world beater that will benfit MANkind. 10 bagger, who knows...that may just be the beginning. Happens very few times I know but that is why we are investing in AIM......

You are right Scot - I had a tenbagger with PDX and may be getting carried away. However, the news is an enormous step forward and may be a worldwide breakthough for the health of men.

Just in case anyone missed this this morning:

Mediwatch Prostate Cancer Diagnosis


RNS Number:5550T
Mediwatch PLC
23 March 2007


Issued on behalf of Mediwatch plc
Date: Friday 23 March 2007
Embargoed: 7.00am

Mediwatch plc
Major Breakthrough in Prostate Cancer Diagnosis

An innovative new test which can help detect the presence of prostate cancer in
10 minutes has been developed by a British biomedical company, Mediwatch plc
(AIM; MDW) ("the Company").

This advance provides a better chance to diagnose and treat a disease
responsible for the deaths of over 10,000 men annually in the UK alone.

In addition, the test, called PSAwatch, is simple and swift to use such that it
can be carried out by nursing staff at a local GP surgery.

It is believed that the test could finally equip doctors with the technology to
begin an affordable nationwide early prostate cancer detection programme for all
men.

Said prostate cancer consultant urologist and director of Mediwatch plc Omer
Karim:

"This test does in minutes what currently takes days.

"It will enable doctors to detect the first signs of prostate cancer faster than
ever before - and save patients days of anxious waiting for results to return."

PSAwatch uses a single, minute sample of blood to detect raised level of
Prostate Specific Antigen - a reliable indicator that the patient may be
suffering from an enlarged prostate gland or prostate cancer.

The intensity of a marker on a test strip is measured by a reading device the
size of a packet of sugar.

It reveals whether there is cause for concern, enabling doctors to arrange
further treatment there and then.

By comparison, current practice depends on samples of blood being sent to highly
skilled technicians in outside laboratories using expensive, bulky and much
slower equipment.

Days often elapse before the results are returned, and patients then have to
make a second appointment with their GP to be given the news, creating even
further delay.

As well as saving time for doctors and patients, PSAwatch is much cheaper to
operate.

Each test costs approximately ONE THIRD of the current practice costs, helping
health care authorities save badly needed cash.

Prostate cancer is one of the fastest increasing causes of death in men around
the globe.

PSAwatch is the latest innovation to emerge from Rugby-based biomedical company
Mediwatch plc.

The Company is already a leading player in the development of portable,
affordable urological equipment used in hospitals across the UK and around the
world.

Said Mediwatch plc Chief Executive Officer Philip Stimpson:

"We believe we have a world beater on our hands.

"PSAwatch is the only truly portable point-of-care prostate cancer diagnosis
machine in existence.

"It is small enough and cheap enough to have a place in every GP's surgery as
well as every hospital across the UK.

"The directors believe that there is no doubt that this is a major step towards
successfully combating a disease which is affecting millions of men across the
globe."

PSAwatch has already been approved for use in all countries across Europe.
Approval for use in other countries is expected shortly.

Enquires:
Mediwatch plc Wonderful PR
Philip Stimpson, Chief Executive Alan Sleator
Kevin Middis, Finance Director Tel: +44 (0) 1438 817760
Tel: +44 (0) 1788 547888 Mobile: + (0)7958 480843
www.mediwatch.com
Ticker: AIM : MDW

Citigate Dewe Rogerson Canaccord Adams Limited
Fiona Tooley, Director Andrew Chubb/Mark Williams
Katie Dale, Senior Account Manager Tel: +44 (0) 20 7050 6500
Tel: +44 (0) 121 455 8370

Editors Note:

Mediwatch plc:
Founded in 1995, Mediwatch plc ("Mediwatch") has developed a range of medical
equipment for the diagnosis of urological disorders. The business focuses its
design skills towards diagnostic products that can be used across the medical
profession. With the acquisition of the Medtronic Urodynamics business,
completed in December 2006, Mediwatch added a number of complementary and well
established capital equipment and disposable products to Mediwatch's existing
range. PSAwatchTM enhances this range of disposable products.

New Developments in PSA Testing:
http://urologycentrelondon.co.uk/news_psadevelopments.html

Prostate Cancer and Prostatic Diseases, written by Omer Karim, Consultant
Urological Surgeon and Mediwatch Director and co-author Mark Emberton,
Consultant Urologist:
http://www.nature.com/doifinder/10.1038/sj.pcan.4500962

Good to see Elemental Healthcare have PSAwatch as their featured product now
:-)

http://www.elemental-healthcare.co.uk/

short again at 13.75 s/b

treble this company rocks, loads of money to be made long, don`t crash and burn dude.

lol at Treble

short away

treble,
If only you had gone long when I said, LOL! and you said boring, LOL!

Treblewide - 20 Mar 2007 09:41 - 1452 of 1466
closed out s/b short for a few points on the plus side....boring
Minder - 20 Mar 2007 10:45 - 1453 of 1466
Are you going long now treble?

who cares?

calm down scotinvestor...its only a commercial